logo

For the Inventor, By the Inventor

South San Francisco, CA, United States of America

Principia Biopharma Inc.


USPTO Granted Patents = 51



Trademarks = 22

Forward Citations = 346

Loading Chart...
Loading Chart...

57 inventors (with patents filed for the assignee):

goldMedal Kenneth Albert Brameld (17 out of 27 patents)

silverMedal David Michael Goldstein (16 out of 62 patents)

bronzeMedal Mohammad Reza Masjedizadeh (12 out of 12 patents)

4.  Erik J Verner (12 out of 83 patents)

5.  Timothy D Owens (10 out of 31 patents)

6.  Tim Owens (6 out of 6 patents)

7.  Steven Gourlay (6 out of 6 patents)

8.  Jiang Zhu (6 out of 6 patents)

9.  Pasit Phiasivongsa (6 out of 6 patents)

10.  Yan Lou (5 out of 74 patents)

11.  Kolbot By (5 out of 6 patents)

12.  Katherine A Chu (2 out of 3 patents)

13.  Dolca Thomas (2 out of 2 patents)

14.  Claire Langrish (2 out of 2 patents)

15.  Wu Lin (2 out of 7 patents)


Core Competencies:
Immunoproteasome Inhibitors
Tyrosine Kinase Inhibitors
FGFR Inhibitors
Quinolone Derivatives
Pyrazolo[3,4-d]pyrimidines
Substituted Pyrazolo Compounds
Modified Release Formulations
Crystalline Forms
Benzimidazole Derivatives
JAK3 Inhibitors
Azaindole Derivatives
Treatment of Pemphigus

51 patents:

1. 12410176 - Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (2025-09-09),
2. 12336999 - Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl) pyrazolo[3,4-d] pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl) piperazin-1-yl]pent-2-enenitrile (2025-06-24),
3. 12312370 - Immunoproteasome inhibitors (2025-05-27),
4. 12281120 - Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile (2025-04-21),
5. 12281110 - Processes for preparing an FGFR inhibitor (2025-04-21),
6. 12178818 - Methods for treating immune thrombocytopenia by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (2024-12-31),
7. 12024531 - Immunoproteasome inhibitors (2024-07-02),
8. 11872229 - Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (2024-01-16),
9. 11827656 - Immunoproteasome inhibitors (2023-11-28),
10. 11814390 - Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (2023-11-14),
11. 11708370 - Solid forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (2023-07-25),
12. 11667641 - Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile (2023-06-06),
13. 11583533 - Topical pharmaceutical compositions comprising 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile (2023-02-21),
14. 11369613 - Salts and solid form of a BTK inhibitor (2022-06-28),
15. 11225493 - Immunoproteasome inhibitors (2022-01-18),
Principia Biopharma Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for immune-mediated diseases. With their proprietary Tailored Covalency® platform, they design and optimize small molecule drugs that target specific proteins involved in various autoimmune disorders, inflammatory diseases, and oncology indications. Principia Biopharma aims to provide effective and safe treatment options to patients through their innovative and precise approach to drug development.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

51 Patents

#28 in South San Francisco, CA

#1,577 in California

#6,657 in US

#13,365 in the World

...
South San Francisco, CA, United States of America

Principia Biopharma Inc.

Forward Citations = 346

57 inventors:

goldMedal Kenneth Albert Brameld (17 out of 27 patents)

silverMedal David Michael Goldstein (16 out of 62 patents)

bronzeMedal Mohammad Reza Masjedizadeh (12 out of 12 patents)

4.  Erik J Verner (12 out of 83 patents)

5.  Timothy D Owens (10 out of 31 patents)

Please report any incorrect information to support@idiyas.com
Loading…